This website is intended for healthcare professionals only

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Share this article

Follow by Email
Facebook
Twitter

Ablation technologies for cardiac arrhythmias

Thomas Fink
14 May, 2015  

Novel ablation tools with innovative catheter designs have been introduced to overcome potential limitations of currently available radiofrequency-based ablation catheters

Thomas Fink MD

Karl-Heinz Kuck MD

Andreas Metzner MD

Department of Cardiology,

Asklepios Klinik St Georg, Hamburg, Germany

Catheter ablation has become a standard treatment option for patients suffering from cardiac arrhythmias. Within the last two decades many methodological efforts have been made to facilitate ablation procedures and to make them safer and more time efficient. This article summarises recent developments in catheter ablation technologies focusing especially on the treatment of atrial fibrillation (AF).

Catheter ablation of atrial fibrillation

AF is the most common cardiac arrhythmia with an incidence of 1.5–2% in the general population.1 Recent guidelines recommend catheter ablation for patients suffering from symptomatic drug-refractory AF and suggest catheter ablation as a first-line therapy in patients with paroxysmal AF (PAF) when performed in experienced centres.1 All electrophysiological interventions target the elimination of focal triggers or arrhythmogenic substrates being essential for the initiation and/or the maintenance of AF, respectively. Most ablation strategies for AF include a wide area circumferential ablation (WACA) of the pulmonary veins (PV) since the PVs have been identified as the most common site of triggers inducing and maintaining AF.2

PV isolation (PVI) is performed by creating transmural myocardial lesions inside the left atrium (LA) around each or both ipsilateral ostia of the PVs.3 The procedure is carried out by transvenous access of the diagnostic and ablation catheters to the atria guided by fluoroscopy and 3D-mapping systems. Additional ablation strategies to PVI were developed to increase the acute and long-term success especially for patients suffering from persistent (more than one week duration) and long-standing persistent (more than one year duration) AF. These strategies include the creation of additional linear lesions4,5 and/or ablation of complex fractionated atrial electrograms (CFAE) inside the LA and/or the right atrium.6

Data from our EP laboratory show five-year clinical success rates between 46.6% (after a single procedure) and up to 79.9% (after multiple procedures) in patients suffering from PAF.7 Further data from our centre show significantly lower five-year success rates for the ablation of long-standing persistent AF with 20.3% of patients maintaining sinus rhythm after a single procedure and 45.0% after multiple procedures, respectively, when performing the Hamburg sequential ablation approach.8 Interestingly, in both cohorts the majority of patients with recurrent AF showed a recovered LA-PV conduction. 

Consequently, novel ablation technologies focus first on reducing the significant rate of electrical reconnection in previously isolated PVs and second to facilitate the ablation procedures. The formation of contiguous and transmural lesions is a prerequisite for permanent electric isolation of the targeted areas. However, the manual radio frequency current (RF)-based ablation approach for AF in a point-by-point fashion is technically challenging, time-consuming and it is difficult to create durable transmural lesions. To solve these difficulties, new catheter-based ablation systems incorporating alternative energy sources were introduced and evaluated during recent years, including new RF ablation catheters, circular ablation catheters and balloon-based ablation devices.

Contact force catheters 

As described above, the creation of durable transmural lesions is of crucial importance for the success of ablation procedures. However, it depends on several factors such as wall contact, catheter stability, delivered temperature, power settings and impedance. Contact force (CF) between the ablation electrode and the myocardium has been found to be a new key factor to effective lesion formation.  Low CF results in inadequate lesion formation, while high CF may increase the risk for complications such as perforation of the myocardium, steam pop or thrombus formation. Although CF has been recognised as an important parameter during ablation, measurements were only possible applying indirect surrogate parameters such as impedance. Recently, different catheters were introduced which allow for direct measurement of the CF. 

The TactiCath Quartz (Endosense/ St. Jude Medical, St. Paul, Minnesota, USA) is an irrigated ablation catheter with a fibre optic sensor to measure CF. This catheter can determine CF changes with a sensitivity of 1g and can be incorporated into the 3D-mapping system EnSite NavX (St. Jude Medical, St. Paul, Minnesota, USA). Two recent multicentre clinical trials evaluated the TactiCath system for AF ablation. The TOCCATA study and the EFFICAS I study could prove direct correlation between low mean CF and high rates of electrical reconduction in previously isolated PVs and recurrence of AF after PVI using the TactiCath system.9 The EFFICAS I study demonstrated direct correlation of areas of low CF and gap formation in ablation lesions after PVI.10 The second CF catheter is the Thermocool Smarttouch catheter (Biosense Webster Inc., Diamond Bar, California, USA). It uses a spring connection between the catheter tip and the shaft to measure CF via microdeflection recordings. In the recently published prospective multicentre SMART-AF trial, Natale et al. could demonstrate a promising 12-month single-procedure success rate of AF-freedom of 72.5% in a cohort of patients suffering from PAF.11 Furthermore, they could show a significantly higher success rate in cases where on average more than 80% of CF within the predefined range was applied. The 12-month success rate raised to 81% after one procedure compared to only 66% if procedures were performed with CF values out of the operators selected working ranges.11 Therefore, the present trial shows a direct correlation between procedural long-term success and correctly applied CF during ablation.

Circular and balloon ablation catheters

During recent years, several new circular and balloon-based ablation devices have been introduced. In general, these types of catheters aim to facilitate PVI and to shorten procedure times. Two circular multi-electrode RF catheters are currently in clinical use. The pulmonary vein ablation catheter (PVAC, Medtronic Ablation Frontiers, Carlsbad, California, USA) is a non-irrigated circular catheter using duty-cycled RF energy. The system allows energy delivery via all or selected electrodes. Although being able to reduce both procedure and fluoroscopy times, the system failed in proving superiority to conventional RF ablation in smaller randomised, prospective trials, as demonstrated in a recently published meta-analysis.12

Of note, recent studies raised safety issues due to a higher rate of observed silent cerebral embolic lesions after PVAC ablation as compared to other catheter designs.13 The clinical significance of these finding remains unclear, nonetheless this issue needs to be solved before routine clinical use of this device can be recommended. Another circular multi-electrode catheter, the nMARQ (Biosense Webster, Diamond Bar, California, USA), allows for either uni- or bipolar RF ablation via 10 selected electrodes with simultaneous recordings of ostial PV electrograms to guide RF application (Figure 1). The use of irrigated RF energy offers possible reduction of silent cerebral microembolisation and improved lesion formation. Two initial studies were able to demonstrate a high acute procedure success and a beneficial safety profile using the nMARQ catheter.14,15

Reports on the incidence of cerebral embolisms describe 33% and 0%, respectively. These inconsistent observations may be attributable to different energy settings and possible electrode overlapping in the ablation attempts of the former group of patients. In another study by Rillig et al. the incidence of oesophageal thermal injury after nMARQ-based PVI was described with 50% after use of the initially recommended energy settings.16 After modification of the ablation protocol, oesophageal lesions were observed in 6.7%, which is comparable to other ablation systems.16 Data on mid- and long-term efficacy is sparse. In conclusion, further studies focusing on safety issues and long-term clinical results are necessary before a final evaluation can be made.

In addition to these technical developments using RF energy, three different balloon-based ablation systems incorporating various energy sources were introduced. The Endoscopic Ablation System (EAS) (CardioFocus, Marlborough, MA, USA) is equipped with a laser energy source and allows visually guided ablation via endoscopic imaging (Figure 2). The system consists of a deflectable sheath of 12F diameter and a balloon ablation catheter comprising an endoscope with a diameter of 2F and a 980nm laser generator. The endoscope enables the operator to apply laser applications and ablation lines under visual control. Different to other balloon-based systems, the compliant balloon allows for adaptation according to the individual PV diameter. The EAS offers point-by-point ablation under optical control without the challenge of achieving a stable catheter position at each ablation spot.

Additionally, the EAS allows for energy titration between 5.5W and 12W. Accordingly the usage of lower ablation energy along the posterior atrial wall contributes to avoid damage to adjacent extracardiac anatomical structures such as the phrenic nerve or the oesophagus, while along the thicker anterior wall higher energy settings can be applied.17 One-year clinical follow-up data from our institution and an international multicentre study could assess a success rate of 60% after a single procedure of antiarrhythmic medication in patients with PAF.18,19 This success rate is comparable to reported results after conventional RF ablation. Concerning the safety profile, a higher degree of ulcered oesophageal lesions in patients treated with the EAS as compared to patients treated with RF energy20 and a rate of 2.5% of patients suffering from phrenic nerve palsy was observed.18 However, no case of significant PV stenosis was described.

The most established balloon-based ablation system is the Arctic Front cryoballoon (Medtronic CryoCath LP, Quebec, Canada). The Cryoballoon (CB) was introduced about 10 years ago. Since then, multiple studies assessed high acute success rates and promising long-term outcomes after CB-based PVI in PAF. One-year clinical long-term success after PVI using the first generation CB was 72.83%, as shown in a recent meta-analysis.21 In addition Neumann et al. reported a five-year clinical success rate of 53% after a single procedure, which is comparable to a five-year result of 46.6% obtained after RF ablation at our centre.7

In a prospective observational study by Vogt et al. rates of freedom from atrial tachyarrhythmias after first generation CB-based PVI were 61.6% after a single procedure and 76.2% after multiple procedures as seen in a 30-month clinical follow-up.22 Several smaller, non-randomised studies compared the first generation CB to conventional and phased RF ablation strategies and proved non-inferiority of the balloon device in PAF.21 Currently, there is a lack on data of CB-based ablation of persistent AF.

Beneath this favourable efficacy, the safety profile of the first generation CB seemed to be comparable to RF ablation with low rates of oesophageal lesions and PV stenosis. However, higher incidences of phrenic nerve palsy were documented.21 Meanwhile, the second generation CB was introduced and features an improved refrigerant injection system with additional distal injection jets providing a more homogenous cooling of the complete northern balloon hemisphere (Figure 3). 

Recently published results of 12-month clinical follow-up after ablation of patients suffering from PAF seem to be promising. Data from our centre demonstrated freedom from AF after a single procedure without antiarrythmic drugs in 80% (39 out of a total of 49) patients.23 Other groups assessed even better results with 83% of patients holding sinus rhythm after one year.24,25 The incidence of phrenic nerve paralysis is reported as 3.5–5.4%25,26 and thus comparable to the incidence after first generation CB ablation.20 The incidence of oesophageal thermal lesions increased to 12–19%.27,28 However, safety cut-offs having a high sensitivity and specificity were developed to prevent these oesophageal lesions28,29 and could successfully reduce the incidence of thermal lesions to 3.2%.29 The currently ongoing “Fire and Ice” study is the first comparing long-term efficacy after second generation CB ablation to conventional RF ablation in a prospective, randomised, multicentre fashion. Recruitment is not expected to be finished until the end of 2015. This study will help to clarify the future role of the second generation CB in catheter ablation of PAF.

Another balloon device incorporating high-intensity focused ultrasound (ProRhythm, Ronkonkoma, NY, USA), is not in clinical use anymore after the occurrence of severe clinical complications, including fatal outcomes after atrio-oesophageal fistula have occurred.30

Conclusions

Catheter ablation of AF is still challenging. Several technological efforts were made and supported by multiple study results to overcome the limitations and to improve procedure feasibility, safety and success.

References

  1. Camm J et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–47.
  2. Haissaguerre M et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659–66.
  3. Pappone C et al. Circumferential radiofrequency ablation of pulmonary vein ostia : A new anatomic approach for curing atrial fibrillation. Circulation 2000;102:2619–28.
  4. Oral H et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006;354:934–41.
  5. Willems S et al. Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison. Eur Heart J 2006;27:2871–8. 
  6. Oral H et al. A randomized assessment of the incremental role of ablation of complex fractionated atrial electrograms after antral pulmonary vein isolation for long-lasting persistent atrial fibrillation. J Am Coll Cardiol 2009;53:782–9.
  7. Ouyang F et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 2010;122:2368–77.
  8. Tilz RR et al. Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol 2012;60:1921–9.
  9. Reddy VY et al. The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. Heart Rhythm 2012;9:1789–95.
  10. Neuzil P et al. Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment: results from the EFFICAS I study. Circ Arrhythm Electrophysiol 2013;6:327–33.
  11. Natale A. et al. Paroxysmal AF Catheter Ablation With a Contact Force Sensing Catheter. J Am Coll Cardiol 2014;64:547–56.
  12. Andrade JG. et al. Efficacy and safety of atrial fibrillation ablation with phased radiofrequency energy and multielectrode catheters. Heart Rhythm 2012;9, 289–96.
  13. Siklody CH et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol 2011;58:681–8.
  14. Deneke T et al. Acute safety and efficacy of a novel multipolar irrigated radiofrequency ablation catheter for pulmonary vein isolation. J Cardiovasc Electrophysiol 2013;25:339–45.
  15. Scaglione M et al. Pulmonary vein isolation with a new multipolar irrigated radiofrequency ablation catheter (nMARQTM ): Feasibility, acute and short-term efficacy, safety, and impact on postablation silent cerebral ischemia. J Cardiovasc Electrophysiol 2014;25(12):1299–305.
  16. Rillig A et al. Modified energy settings are mandatory to minimize oesophageal injury using the novel multipolar irrigated radiofrequency ablation catheter for pulmonary vein isolation. 2014. Europace published ahead of print.
  17. Metzner A et al. The influence of varying energy settings on efficacy and safety of endoscopic pulmonary vein isolation. Heart Rhythm 2012;9:1380–5.
  18. Dukkipati SR et al. Pulmonary vein isolation using a visually guided laser balloon catheter: the first 200-patient multicenter clinical experience. Circ Arrhythm Electrophysiol 2013;6:467–72.
  19. Metzner A et al. One-year clinical outcome after pulmonary vein isolation using the novel endoscopic ablation system in patients with paroxysmal atrial fibrillation. Heart Rhythm 2011a;8:988–93.
  20. Metzner A et al. Esophageal temperature change and esophageal thermal lesions after pulmonary vein isolation using the novel endoscopic ablation system. Heart Rhythm 2011b;8:815–20.
  21. Andrade JG et al. Efficacy and safety of cryoballoon ablation for atrial fibrillation: A systematic review of published studies. Heart Rhythm 2011;8:1444–51.
  22. Vogt J et al. Long-term outcomes after cryoballoon pulmonary vein isolation. J Am Coll Cardiol 2013;61:1707–12.
  23. Metzner A. et al. One-year clinical outcome after pulmonary vein isolation using the second-generation 28-mm cryoballoon. Circ Arrhythm Electrophysiol 2014a;7:288–92.
  24. Chierchia G et al. Second-generation cryoballoon ablation for paroxysmal atrial fibrillation : 1-year follow-up. Europace 2014;16:639–44.
  25. Fuernkranz AF et al. Improved 1-year clinical success rate of pulmonary vein isolation with the second-generation cryoballoon in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2014;25:840–4.
  26. Metzner A et al. The incidence of phrenic nerve injury during pulmonary vein isolation using the second-generation 28 mm cryoballoon. J Cardiovasc Electrophysiol 2014b;25:466–70.
  27. Fürnkranz A et al. Luminal esophageal temperature predicts esophageal lesions after second-generation cryoballoon pulmonary vein isolation. Heart Rhythm 2013;10:789–93.
  28. Metzner A et al. Increased incidence of esophageal thermal lesions using the second-generation 28-mm Cryoballoon. Circ Arrhythm Electrophysiol 2013;6:769–75.
  29. Fürnkranz A et al. Reduced incidence of esophageal lesions by luminal esophageal temperature-guided second-generation cryoballoon ablation. Heart Rhythm 2015;12(2):268–74.
  30. Neven K et al. Two-year clinical follow-up after pulmonary vein isolation using high-intensity focused ultrasound (HIFU) and an esophageal temperature-guided safety algorithm. Heart Rhythm 2012;9:407–13.